Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-10-05

AUTHORS

Pratik Sinha, Kevin L. Delucchi, B. Taylor Thompson, Daniel F. McAuley, Michael A. Matthay, Carolyn S. Calfee

ABSTRACT

PurposeUsing latent class analysis (LCA), we have consistently identified two distinct subphenotypes in four randomized controlled trial cohorts of ARDS. One subphenotype has hyper-inflammatory characteristics and is associated with worse clinical outcomes. Further, within three negative clinical trials, we observed differential treatment response by subphenotype to randomly assigned interventions. The main purpose of this study was to identify ARDS subphenotypes in a contemporary NHLBI Network trial of infection-associated ARDS (SAILS) using LCA and to test for differential treatment response to rosuvastatin therapy in the subphenotypes.MethodsLCA models were constructed using a combination of biomarker and clinical data at baseline in the SAILS study (n = 745). LCA modeling was then repeated using an expanded set of clinical class-defining variables. Subphenotypes were tested for differential treatment response to rosuvastatin.ResultsThe two-class LCA model best fit the population. Forty percent of the patients were classified as the “hyper-inflammatory” subphenotype. Including additional clinical variables in the LCA models did not identify new classes. Mortality at day 60 and day 90 was higher in the hyper-inflammatory subphenotype. No differences in outcome were observed between hyper-inflammatory patients randomized to rosuvastatin therapy versus placebo.ConclusionsLCA using a two-subphenotype model best described the SAILS population. The subphenotypes have features consistent with those previously reported in four other cohorts. Addition of new class-defining variables in the LCA model did not yield additional subphenotypes. No treatment effect was observed with rosuvastatin. These findings further validate the presence of two subphenotypes and demonstrate their utility for patient stratification in ARDS. More... »

PAGES

1859-1869

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00134-018-5378-3

DOI

http://dx.doi.org/10.1007/s00134-018-5378-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1107429770

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30291376


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Acute Lung Injury", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cohort Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hydroxymethylglutaryl-CoA Reductase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Latent Class Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Respiratory Distress Syndrome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rosuvastatin Calcium", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sepsis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, 505 Parnassus Ave, Box 0111, 94143-0111, San Francisco, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.266102.1", 
          "name": [
            "Department of Medicine, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, 505 Parnassus Ave, Box 0111, 94143-0111, San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sinha", 
        "givenName": "Pratik", 
        "id": "sg:person.01011732634.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01011732634.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Psychiatry, University of California, San Francisco, San Francisco, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.266102.1", 
          "name": [
            "Department of Psychiatry, University of California, San Francisco, San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Delucchi", 
        "givenName": "Kevin L.", 
        "id": "sg:person.01036655722.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036655722.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Division of Pulmonary and Critical Care, Massachusetts General Hospital, Boston, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.32224.35", 
          "name": [
            "Department of Medicine, Division of Pulmonary and Critical Care, Massachusetts General Hospital, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thompson", 
        "givenName": "B. Taylor", 
        "id": "sg:person.07544422077.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07544422077.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK", 
          "id": "http://www.grid.ac/institutes/grid.416232.0", 
          "name": [
            "Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen\u2019s University of Belfast, Belfast, UK", 
            "Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McAuley", 
        "givenName": "Daniel F.", 
        "id": "sg:person.013052706317.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013052706317.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.266102.1", 
          "name": [
            "Department of Medicine, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, 505 Parnassus Ave, Box 0111, 94143-0111, San Francisco, CA, USA", 
            "Department of Anesthesia, University of California, San Francisco, San Francisco, CA, USA", 
            "Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matthay", 
        "givenName": "Michael A.", 
        "id": "sg:person.01066335761.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066335761.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.266102.1", 
          "name": [
            "Department of Medicine, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, 505 Parnassus Ave, Box 0111, 94143-0111, San Francisco, CA, USA", 
            "Department of Anesthesia, University of California, San Francisco, San Francisco, CA, USA", 
            "Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Calfee", 
        "givenName": "Carolyn S.", 
        "id": "sg:person.01222460111.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222460111.09"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/s12916-015-0368-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014024230", 
          "https://doi.org/10.1186/s12916-015-0368-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00134-006-0251-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029466900", 
          "https://doi.org/10.1007/s00134-006-0251-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/10898570-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010268448", 
          "https://doi.org/10.2165/10898570-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1741-7015-7-34", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024284364", 
          "https://doi.org/10.1186/1741-7015-7-34"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/cc8872", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007684107", 
          "https://doi.org/10.1186/cc8872"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-10-05", 
    "datePublishedReg": "2018-10-05", 
    "description": "PurposeUsing latent class analysis (LCA), we have consistently identified two distinct subphenotypes in four randomized controlled trial cohorts of ARDS. One subphenotype has hyper-inflammatory characteristics and is associated with worse clinical outcomes. Further, within three negative clinical trials, we observed differential treatment response by subphenotype to randomly assigned interventions. The main purpose of this study was to identify ARDS subphenotypes in a contemporary NHLBI Network trial of infection-associated ARDS (SAILS) using LCA and to test for differential treatment response to rosuvastatin therapy in the subphenotypes.MethodsLCA models were constructed using a combination of biomarker and clinical data at baseline in the SAILS study (n\u2009=\u2009745). LCA modeling was then repeated using an expanded set of clinical class-defining variables. Subphenotypes were tested for differential treatment response to rosuvastatin.ResultsThe two-class LCA model best fit the population. Forty percent of the patients were classified as the \u201chyper-inflammatory\u201d subphenotype. Including additional clinical variables in the LCA models did not identify new classes. Mortality at day 60 and day 90 was higher in the hyper-inflammatory subphenotype. No differences in outcome were observed between hyper-inflammatory patients randomized to rosuvastatin therapy versus placebo.ConclusionsLCA using a two-subphenotype model best described the SAILS population. The subphenotypes have features consistent with those previously reported in four other cohorts. Addition of new class-defining variables in the LCA model did not yield additional subphenotypes. No treatment effect was observed with rosuvastatin. These findings further validate the presence of two subphenotypes and demonstrate their utility for patient stratification in ARDS.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00134-018-5378-3", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2683958", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2784459", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.7211815", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.4899024", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.5475488", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1313639", 
        "issn": [
          "0342-4642", 
          "1432-1238"
        ], 
        "name": "Intensive Care Medicine", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "11", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "44"
      }
    ], 
    "keywords": [
      "differential treatment response", 
      "treatment response", 
      "ARDS subphenotypes", 
      "latent class analysis", 
      "worse clinical outcomes", 
      "additional clinical variables", 
      "combination of biomarkers", 
      "negative clinical trials", 
      "trial cohort", 
      "clinical outcomes", 
      "clinical variables", 
      "distinct subphenotypes", 
      "clinical trials", 
      "sepsis studies", 
      "clinical data", 
      "day 90", 
      "patient stratification", 
      "Network trial", 
      "secondary analysis", 
      "class analysis", 
      "ARDS", 
      "day 60", 
      "subphenotypes", 
      "SAiL study", 
      "treatment effects", 
      "patients", 
      "therapy", 
      "cohort", 
      "trials", 
      "outcomes", 
      "placebo", 
      "response", 
      "statins", 
      "lung", 
      "rosuvastatin", 
      "population", 
      "mortality", 
      "baseline", 
      "biomarkers", 
      "study", 
      "intervention", 
      "percent", 
      "stratification", 
      "findings", 
      "variables", 
      "differences", 
      "analysis", 
      "effect", 
      "utility", 
      "presence", 
      "combination", 
      "purpose", 
      "data", 
      "addition", 
      "model", 
      "new class", 
      "features", 
      "characteristics", 
      "LCA model", 
      "main purpose", 
      "class", 
      "ConclusionsLCA", 
      "set", 
      "modeling", 
      "LCA modeling"
    ], 
    "name": "Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study", 
    "pagination": "1859-1869", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1107429770"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00134-018-5378-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30291376"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00134-018-5378-3", 
      "https://app.dimensions.ai/details/publication/pub.1107429770"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:02", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_764.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00134-018-5378-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00134-018-5378-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00134-018-5378-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00134-018-5378-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00134-018-5378-3'


 

This table displays all metadata directly associated to this object as RDF triples.

259 TRIPLES      21 PREDICATES      109 URIs      96 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00134-018-5378-3 schema:about N10303602bb874a1390bec0805a31bdd8
2 N55b170af47ec411b8755e3f405d8cb56
3 N7c040aa84fbf426aa13ab8aa9c5c44ef
4 N8173eb500f0145b2a819a0c5cf45bbf7
5 N9883f7eec9424ef78ed5eb1ed89c4b11
6 N9be813cfbeec488cb632f2e4a456ef65
7 Na2e53ccecc6e4fc6947283017c1d87f1
8 Na453aa7db11a4926b3771fc4c2035eab
9 Nb3fb778d1d674a2f81b9f89e12e244ef
10 Nc0c1b2249c2243679458cf1382ef10b0
11 Nc29bdda3957d481f860aa39c5b21d4f8
12 Nd72c2e169e14434b82635a4f2ca3f3ec
13 Neb798b27d17d43a4bd28240cf7046098
14 Nfd54bd18f5c64fa59fe58f98eabddd10
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author N94958e42da9142b88ef3dc9d340d0896
18 schema:citation sg:pub.10.1007/s00134-006-0251-1
19 sg:pub.10.1186/1741-7015-7-34
20 sg:pub.10.1186/cc8872
21 sg:pub.10.1186/s12916-015-0368-6
22 sg:pub.10.2165/10898570-000000000-00000
23 schema:datePublished 2018-10-05
24 schema:datePublishedReg 2018-10-05
25 schema:description PurposeUsing latent class analysis (LCA), we have consistently identified two distinct subphenotypes in four randomized controlled trial cohorts of ARDS. One subphenotype has hyper-inflammatory characteristics and is associated with worse clinical outcomes. Further, within three negative clinical trials, we observed differential treatment response by subphenotype to randomly assigned interventions. The main purpose of this study was to identify ARDS subphenotypes in a contemporary NHLBI Network trial of infection-associated ARDS (SAILS) using LCA and to test for differential treatment response to rosuvastatin therapy in the subphenotypes.MethodsLCA models were constructed using a combination of biomarker and clinical data at baseline in the SAILS study (n = 745). LCA modeling was then repeated using an expanded set of clinical class-defining variables. Subphenotypes were tested for differential treatment response to rosuvastatin.ResultsThe two-class LCA model best fit the population. Forty percent of the patients were classified as the “hyper-inflammatory” subphenotype. Including additional clinical variables in the LCA models did not identify new classes. Mortality at day 60 and day 90 was higher in the hyper-inflammatory subphenotype. No differences in outcome were observed between hyper-inflammatory patients randomized to rosuvastatin therapy versus placebo.ConclusionsLCA using a two-subphenotype model best described the SAILS population. The subphenotypes have features consistent with those previously reported in four other cohorts. Addition of new class-defining variables in the LCA model did not yield additional subphenotypes. No treatment effect was observed with rosuvastatin. These findings further validate the presence of two subphenotypes and demonstrate their utility for patient stratification in ARDS.
26 schema:genre article
27 schema:isAccessibleForFree true
28 schema:isPartOf N1132af6d48824bacb88da460213469be
29 N7bda7b52355d4a658dc71d3400769dd4
30 sg:journal.1313639
31 schema:keywords ARDS
32 ARDS subphenotypes
33 ConclusionsLCA
34 LCA model
35 LCA modeling
36 Network trial
37 SAiL study
38 addition
39 additional clinical variables
40 analysis
41 baseline
42 biomarkers
43 characteristics
44 class
45 class analysis
46 clinical data
47 clinical outcomes
48 clinical trials
49 clinical variables
50 cohort
51 combination
52 combination of biomarkers
53 data
54 day 60
55 day 90
56 differences
57 differential treatment response
58 distinct subphenotypes
59 effect
60 features
61 findings
62 intervention
63 latent class analysis
64 lung
65 main purpose
66 model
67 modeling
68 mortality
69 negative clinical trials
70 new class
71 outcomes
72 patient stratification
73 patients
74 percent
75 placebo
76 population
77 presence
78 purpose
79 response
80 rosuvastatin
81 secondary analysis
82 sepsis studies
83 set
84 statins
85 stratification
86 study
87 subphenotypes
88 therapy
89 treatment effects
90 treatment response
91 trial cohort
92 trials
93 utility
94 variables
95 worse clinical outcomes
96 schema:name Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study
97 schema:pagination 1859-1869
98 schema:productId N356c76ac031c4862a0427ef71eb141e1
99 N59d85dd62f2d446894ac327ca9335ea3
100 N8380a62b584d42f4a47ead28683b6130
101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107429770
102 https://doi.org/10.1007/s00134-018-5378-3
103 schema:sdDatePublished 2022-09-02T16:02
104 schema:sdLicense https://scigraph.springernature.com/explorer/license/
105 schema:sdPublisher N8ff341cbae4945479208ea9f77dbd7a5
106 schema:url https://doi.org/10.1007/s00134-018-5378-3
107 sgo:license sg:explorer/license/
108 sgo:sdDataset articles
109 rdf:type schema:ScholarlyArticle
110 N10303602bb874a1390bec0805a31bdd8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Humans
112 rdf:type schema:DefinedTerm
113 N1132af6d48824bacb88da460213469be schema:issueNumber 11
114 rdf:type schema:PublicationIssue
115 N15c1333834c8488092146a99ff7af788 rdf:first sg:person.01036655722.84
116 rdf:rest Nf3eefb919c3e4656b9047bfc4160e663
117 N356c76ac031c4862a0427ef71eb141e1 schema:name pubmed_id
118 schema:value 30291376
119 rdf:type schema:PropertyValue
120 N55b170af47ec411b8755e3f405d8cb56 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Respiratory Distress Syndrome
122 rdf:type schema:DefinedTerm
123 N59d85dd62f2d446894ac327ca9335ea3 schema:name doi
124 schema:value 10.1007/s00134-018-5378-3
125 rdf:type schema:PropertyValue
126 N731f70f5366a4b29bc3f5f6a6757acea rdf:first sg:person.01222460111.09
127 rdf:rest rdf:nil
128 N7bda7b52355d4a658dc71d3400769dd4 schema:volumeNumber 44
129 rdf:type schema:PublicationVolume
130 N7c040aa84fbf426aa13ab8aa9c5c44ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Acute Lung Injury
132 rdf:type schema:DefinedTerm
133 N8173eb500f0145b2a819a0c5cf45bbf7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Latent Class Analysis
135 rdf:type schema:DefinedTerm
136 N8380a62b584d42f4a47ead28683b6130 schema:name dimensions_id
137 schema:value pub.1107429770
138 rdf:type schema:PropertyValue
139 N8ff341cbae4945479208ea9f77dbd7a5 schema:name Springer Nature - SN SciGraph project
140 rdf:type schema:Organization
141 N94958e42da9142b88ef3dc9d340d0896 rdf:first sg:person.01011732634.45
142 rdf:rest N15c1333834c8488092146a99ff7af788
143 N9883f7eec9424ef78ed5eb1ed89c4b11 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Survival Rate
145 rdf:type schema:DefinedTerm
146 N9be813cfbeec488cb632f2e4a456ef65 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Adult
148 rdf:type schema:DefinedTerm
149 Na2e53ccecc6e4fc6947283017c1d87f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Cohort Studies
151 rdf:type schema:DefinedTerm
152 Na453aa7db11a4926b3771fc4c2035eab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Male
154 rdf:type schema:DefinedTerm
155 Nb3fb778d1d674a2f81b9f89e12e244ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Hydroxymethylglutaryl-CoA Reductase Inhibitors
157 rdf:type schema:DefinedTerm
158 Nc0c1b2249c2243679458cf1382ef10b0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Rosuvastatin Calcium
160 rdf:type schema:DefinedTerm
161 Nc29bdda3957d481f860aa39c5b21d4f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Sepsis
163 rdf:type schema:DefinedTerm
164 Nd72c2e169e14434b82635a4f2ca3f3ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Middle Aged
166 rdf:type schema:DefinedTerm
167 Ne48608c903d648ff8a5ce9a00ec47890 rdf:first sg:person.013052706317.18
168 rdf:rest Nff0dcc8bfc4a449e9ba5a0c9f824cc82
169 Neb798b27d17d43a4bd28240cf7046098 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Female
171 rdf:type schema:DefinedTerm
172 Nf3eefb919c3e4656b9047bfc4160e663 rdf:first sg:person.07544422077.04
173 rdf:rest Ne48608c903d648ff8a5ce9a00ec47890
174 Nfd54bd18f5c64fa59fe58f98eabddd10 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Aged
176 rdf:type schema:DefinedTerm
177 Nff0dcc8bfc4a449e9ba5a0c9f824cc82 rdf:first sg:person.01066335761.54
178 rdf:rest N731f70f5366a4b29bc3f5f6a6757acea
179 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
180 schema:name Medical and Health Sciences
181 rdf:type schema:DefinedTerm
182 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
183 schema:name Clinical Sciences
184 rdf:type schema:DefinedTerm
185 sg:grant.2683958 http://pending.schema.org/fundedItem sg:pub.10.1007/s00134-018-5378-3
186 rdf:type schema:MonetaryGrant
187 sg:grant.2784459 http://pending.schema.org/fundedItem sg:pub.10.1007/s00134-018-5378-3
188 rdf:type schema:MonetaryGrant
189 sg:grant.4899024 http://pending.schema.org/fundedItem sg:pub.10.1007/s00134-018-5378-3
190 rdf:type schema:MonetaryGrant
191 sg:grant.5475488 http://pending.schema.org/fundedItem sg:pub.10.1007/s00134-018-5378-3
192 rdf:type schema:MonetaryGrant
193 sg:grant.7211815 http://pending.schema.org/fundedItem sg:pub.10.1007/s00134-018-5378-3
194 rdf:type schema:MonetaryGrant
195 sg:journal.1313639 schema:issn 0342-4642
196 1432-1238
197 schema:name Intensive Care Medicine
198 schema:publisher Springer Nature
199 rdf:type schema:Periodical
200 sg:person.01011732634.45 schema:affiliation grid-institutes:grid.266102.1
201 schema:familyName Sinha
202 schema:givenName Pratik
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01011732634.45
204 rdf:type schema:Person
205 sg:person.01036655722.84 schema:affiliation grid-institutes:grid.266102.1
206 schema:familyName Delucchi
207 schema:givenName Kevin L.
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036655722.84
209 rdf:type schema:Person
210 sg:person.01066335761.54 schema:affiliation grid-institutes:grid.266102.1
211 schema:familyName Matthay
212 schema:givenName Michael A.
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066335761.54
214 rdf:type schema:Person
215 sg:person.01222460111.09 schema:affiliation grid-institutes:grid.266102.1
216 schema:familyName Calfee
217 schema:givenName Carolyn S.
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222460111.09
219 rdf:type schema:Person
220 sg:person.013052706317.18 schema:affiliation grid-institutes:grid.416232.0
221 schema:familyName McAuley
222 schema:givenName Daniel F.
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013052706317.18
224 rdf:type schema:Person
225 sg:person.07544422077.04 schema:affiliation grid-institutes:grid.32224.35
226 schema:familyName Thompson
227 schema:givenName B. Taylor
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07544422077.04
229 rdf:type schema:Person
230 sg:pub.10.1007/s00134-006-0251-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029466900
231 https://doi.org/10.1007/s00134-006-0251-1
232 rdf:type schema:CreativeWork
233 sg:pub.10.1186/1741-7015-7-34 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024284364
234 https://doi.org/10.1186/1741-7015-7-34
235 rdf:type schema:CreativeWork
236 sg:pub.10.1186/cc8872 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007684107
237 https://doi.org/10.1186/cc8872
238 rdf:type schema:CreativeWork
239 sg:pub.10.1186/s12916-015-0368-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014024230
240 https://doi.org/10.1186/s12916-015-0368-6
241 rdf:type schema:CreativeWork
242 sg:pub.10.2165/10898570-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010268448
243 https://doi.org/10.2165/10898570-000000000-00000
244 rdf:type schema:CreativeWork
245 grid-institutes:grid.266102.1 schema:alternateName Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, USA
246 Department of Medicine, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, 505 Parnassus Ave, Box 0111, 94143-0111, San Francisco, CA, USA
247 Department of Psychiatry, University of California, San Francisco, San Francisco, CA, USA
248 schema:name Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, USA
249 Department of Anesthesia, University of California, San Francisco, San Francisco, CA, USA
250 Department of Medicine, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, 505 Parnassus Ave, Box 0111, 94143-0111, San Francisco, CA, USA
251 Department of Psychiatry, University of California, San Francisco, San Francisco, CA, USA
252 rdf:type schema:Organization
253 grid-institutes:grid.32224.35 schema:alternateName Department of Medicine, Division of Pulmonary and Critical Care, Massachusetts General Hospital, Boston, MA, USA
254 schema:name Department of Medicine, Division of Pulmonary and Critical Care, Massachusetts General Hospital, Boston, MA, USA
255 rdf:type schema:Organization
256 grid-institutes:grid.416232.0 schema:alternateName Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK
257 schema:name Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University of Belfast, Belfast, UK
258 Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK
259 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...